In individuals with diabetes and obesity, GLP-1 receptor agonist therapy reduced levels of inflammatory macrophages as well as multiple inflammatory and oxidative markers (e.g., interleukin-6, interleukin-1β, monocyte chemoattractant protein-1, adhesion molecules, prostaglandins, serum amyloid A, tumor necrosis factor-α, toll-like receptors) [41,68]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.